KPRX experienced a dramatic financial deterioration with operating cash flow swinging from $8.6M positive to -$10.0M negative and net income declining from $3.6M profit to -$10.8M loss.
This represents a massive operational turnaround suggesting the company burned through nearly $19M more cash year-over-year while significantly increasing R&D spending. Despite having more cash on hand, the company's equity base eroded by over one-third, indicating potential dilutive financing or asset write-downs that materially weakened the balance sheet.
KPRX's financials show a company in dramatic transition from profitability to significant losses, with operating cash flow declining by over $18M year-over-year while R&D expenses increased 37.5% to $10.8M. The balance sheet contracted substantially with total assets falling 33.5% and stockholders' equity declining 37.4%, though cash reserves nearly doubled to $8.7M likely from external financing. This profile suggests an early-stage biotech company that has pivoted to aggressive R&D spending, burning cash rapidly despite improved liquidity position.
Capital expenditure jumped 1670.9% — major investment cycle underway; assess returns on deployment.
Net income declined 401.4% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Operating cash flow fell 216.4% — earnings quality concerns; investigate working capital changes and non-cash items.
Receivables surged 153.3% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Cash position surged 129.3% — strong cash generation or capital raise providing significant financial cushion.
Current liabilities reduced — improved short-term financial position and working capital health.
R&D investment increased 37.5% — signals commitment to future product development, though near-term margin impact.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Total assets contracted 33.5% — asset sales, write-downs, or balance sheet optimization underway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →